Day: December 23, 2024

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines” or the “Company”), a space exploration, infrastructure, and services company, has secured additional contracts from NASA’s Near Space Network (“NSN”) for Direct-to-Earth (“DTE”) services. These contracts further position Intuitive Machines as a vital partner in supporting NASA’s missions to the Moon, and beyond. DTE communication and navigation services are critical for enabling missions to exit Earth’s orbit, reach lunar destinations, and explore deep space. The new contract awards include:Subcategory 1.2: DTE Geostationary (“GEO”) to Cislunar DTE Services, offering enhanced data transmission capabilities and autonomous operations. Subcategory 1.3: xCislunar DTE Services, addressing mission needs for highly elliptical...

DALLAS, Dec. 23, 2024 (GLOBE NEWSWIRE) — Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, is pleased to announce that on December 20, 2024 the Company received a “moot” letter from Nasdaq confirming that the Company has regained compliance with all applicable listing standards for its continued listing on the Nasdaq Capital Market and that a further hearing regarding the Company’s compliance is no longer necessary. “I am thrilled to announce that we continue to successfully meet our Nasdaq’s compliance standards,” said Dr. Michael DiMaio, Chairman of Spectral AI’s Board of Directors. “This confirmation reflects our team’s...

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life   The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 23 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases,...

Aspo PlcPress releaseDecember 23, 2024 at 2:00 pm Aspo SBTi commitment   Aspo Plc has joined the Science Based Targets initiative (SBTi) and committed to set a near-term company-wide science-based emission reduction target, aiming to limit global warming to 1.5°C in line with the Paris Agreement. This commitment builds on the promise made during the Capital Market Day held in May 2024 and reflects Aspo’s ongoing transformation and sustainability journey. The company is now beginning the process of developing and validating its targets in collaboration with SBTi.    Aspo creates value by owning and developing its businesses sustainably and long term. Our companies aim to be market leaders in their sectors and forerunners in sustainability.    “We want to support the transformation towards net zero across the industries we operate in, and...

Schouw & Co. share buy-back programme, week 51 2024 On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 13/12/2024 345,287 558.11 192,707,988    Monday, 16 December 2024 2,000 538.24 1,076,480    Tuesday, 17 December 2024 2,000 530.18 1,060,360    Wednesday, 18 December 2024 2,000 532.19 1,064,380    Thursday,...

DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that a 14th site is now activated and able to enroll subjects in the NEUTRALIZE-AKI pivotal trial. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company’s proprietary therapeutic Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous renal replacement therapy (CRRT). “We are pleased to welcome the 14th hospital to our trial, especially as this site has been among the top CRRT programs in the country,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “As of today, 70 of the planned...

Castellum, Inc. Announces Pricing of $3.6 Million Registered Direct OfferingCastellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 9,473,700 shares of common stock in a registered direct offering. The shares of common stock are being sold at an offering price of $0.38 per share – https://castellumus.com/VIENNA, Va., Dec. 23, 2024 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional...

TORONTO, Dec. 23, 2024 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”) (TSX VENTURE: PVF) announced today that it has received approval from the TSX Venture Exchange (the “Exchange”) to renew its normal course issuer bids to purchase up to 3,521,732 of its non‐voting equity limited partnership units (the “Equity LP Units”), representing approximately 5% of its currently outstanding Equity LP Units; and to purchase up to 938,226 of its non‐voting Class A preferred limited partnership units, Series 1 (the “Preferred LP Units”), representing approximately 5% of its currently outstanding Preferred LP Units (collectively, the “Bids”). The period of the Bids will be effective from January 3, 2025 to January 2, 2026, or such earlier date that the Partnership completes its purchases. Purchases by the Partnership...